Your browser doesn't support javascript.
loading
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri, M; Mehnert, J; Silk, A W; Jabbour, S K; Ganesan, S; Popli, P; Riedlinger, G; Stephenson, R; de Meritens, A B; Leiser, A; Mayer, T; Chan, N; Spencer, K; Girda, E; Malhotra, J; Chan, T; Subbiah, V; Groisberg, R.
Afiliação
  • Palmeri M; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Mehnert J; Department of Medicine, Perlmutter Cancer Center of NYU Langone Health, NYU Medical School, New York, USA.
  • Silk AW; Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
  • Jabbour SK; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Ganesan S; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Popli P; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Riedlinger G; Department of Pathology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Stephenson R; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • de Meritens AB; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Leiser A; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Mayer T; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Chan N; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Spencer K; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Girda E; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Malhotra J; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA.
  • Chan T; Center of Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, USA.
  • Subbiah V; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Groisberg R; Department of Medicine, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, USA. Electronic address: roman.groisberg@rutgers.edu.
ESMO Open ; 7(1): 100336, 2022 02.
Article em En | MEDLINE | ID: mdl-34953399
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Instabilidade de Microssatélites / Imunoterapia / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Instabilidade de Microssatélites / Imunoterapia / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article